* If you want to update the article please login/register
Abstract Background: To effectively reduce and eliminate rabies in humans, mass vaccination of dogs as a vital rabies reservoir is most recommended. Dog vaccination rates in several developing nations are still dangerously poor due to budget constraints and a high turnover in dog populations. We investigated and optimized the replication and vaccine potency of PV rabies virus strain in the muscovy-duck derived AGE1. CR and AGE1. CR. pIX suspension cell lines in this research. Compared to the parental CR cell line, CR. pIX has been shown to rise heat shock responses and supported marginally higher infectious titers. According to the NIH test, the potency of inactivated rabies virus harvest was 3. 5 IU/ml. Conclusion This research shows that a rabies vaccine for animal vaccination can be produced with a scalable process in chemically defined medium, as shown in the AGE1. CR. pIX suspension cell line.
Source link: https://doi.org/10.1186/s12896-022-00747-5
CORAVAX, a recombinant Rabies virus-vectored SARS-CoV-2 vaccine, as an effective COVID-19 vaccination program, according to this report. In animal models, CORAVAX has been proving immunogenic and protective against SARS-CoV-2. In CORAVAX, we've tested TLR4 agonists, inflammasome catalysts, and Alum adjuvants, and we found that TLR4-activating MPLA-AddaVax had the highest potential. We followed the humoral immune reaction to CORAVAX in mice with pre-existing Rabies virus immunity, and there were no significant differences compared to nau00efve mice. We then followed the immune reaction to CORAVAX over several months and 1 year post-imunization.
Source link: https://doi.org/10.21203/rs.3.rs-1689061/v1
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions